Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 2, 2014

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Chronic Lymphocytic Leukemia

Interventions

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Ruxolitinib Phosphate

Given PO

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER